NEW YORK (GenomeWeb) – Protagen said today that it has granted a semi-exclusive license to San Diego-based Inova Diagnostics for its systemic sclerosis biomarker BICD2.

The license allows Inova to include BICD2 in its portfolio of connective tissue disease reagents aimed at aiding in the diagnosis of systemic sclerosis. Financial terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

Sponsored by

This webinar will discuss an automated, high-throughput method of generating high-quality antigens and antibodies.